Cellectar Biosciences Inc (CLRB)

[Crusader]

I stand corrected, staccani,

I misread the summary below which has accompanied the last few PR’s.

It says there are “three” clinical studies, one a phase 2 and two in phase 1, there are no phase 3 trials that have started. Sorry to post an inaccuracy.



PR SUMMARY LANGUAGE:

“...The company’s lead PDC therapeutic, CLR 131, is currently in three clinical studies – a Phase 2 study, and two Phase 1 studies. The Phase 2 clinical study (CLOVER-1) is in relapsed/refractory (R/R) B-cell malignancies, including multiple myeloma (MM), chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL), lymphoplasmacytic lymphoma (LPL), marginal zone lymphoma (MZL), mantle cell lymphoma (MCL), and diffuse large B-cell lymphoma (DLBCL). The company is also conducting a Phase 1 dose escalation study in patients with R/R multiple myeloma (MM) and a Phase 1 study in pediatric solid tumors and lymphoma...”